| Literature DB >> 34164671 |
Kei Kobayashi1,2,3, Daiki Nakagomi1,2,3, Yoshiaki Kobayashi1,2,3, Chisaki Ajima1,2,3, Shunichiro Hanai1,2,3, Kensuke Koyama3,4, Kei Ikeda5.
Abstract
OBJECTIVE: Recent studies suggest that the knee is frequently involved in PMR. In this study, we aimed to determine whether the US assessment of the shoulder and knee discriminates between PMR and other differential diagnoses and improves the accuracy of the 2012 EULAR/ACR provisional classification criteria for PMR.Entities:
Keywords: classification criteria; ligament inflammation; polymyalgia rheumatica; tendinitis; tenosynovitis; ultrasound
Mesh:
Substances:
Year: 2022 PMID: 34164671 PMCID: PMC8889301 DOI: 10.1093/rheumatology/keab506
Source DB: PubMed Journal: Rheumatology (Oxford) ISSN: 1462-0324 Impact factor: 7.580
Patient demographics and clinical and laboratory data at baseline, and comparison between patients in the PMR-definite, PMR-mimic and RA groups
| PMR-definite | PMR-mimic | RA |
| ||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| Demographics and laboratory data | |||||
| Age, mean ( | 74 (8.1) | 53 (27.1) | 74 (8.1) | <0.0001 | 1 |
| Female, | 35 (58) | 12 (57) | 35 (58) | 0.924 | 1 |
| CRP level, mean ( | 6.52 (4.51) | 1.26 (2.02) | 2.97 (3.58) | <0.0001 | <0.0001 |
| ESR, median (IQR), mm/h | 90 (70–102) | 31 (20–54) | 32 (17–86) | 0.006 | <0.0001 |
| MMP-3, median (IQR), ng/ml | 185 (119–432) | 94 (30–152) | 72 (72–370) | 0.001 | 0.084 |
| 2012 EULAR/ACR classification criteria | |||||
| Morning stiffness duration >45 min, | 57 (95) | 14 (67) | 23 (38) | 0.002 | <0.0001 |
| Hip pain or limited range of motion, | 29 (48) | 4 (19) | 14 (23) | 0.019 | 0.004 |
| Absence of RF or ACPA, | 57 (95) | 21 (100) | 22 (37) | 0.401 | <0.0001 |
| Absence of other joint pain, | 40 (67) | 1 (5) | 0 (0) | <0.0001 | <0.0001 |
| Fulfilment of 4 or more criteria, | 52 (87) | 14 (67) | 12 (20) | 0.048 | <0.0001 |
| Treatment for PMR or RA | |||||
| Glucocorticoids ever, | 60 (100) | 10 (48) | 27 (45) | <0.0001 | <0.0001 |
| Initial dose of glucocorticoids, median (IQR) [range], mg/day (prednisolone equivalent) | 15 (10–15) [5–40] | 0 (0–5) [0–10] | 0 (0–10) [0–20] | <0.0001 | <0.0001 |
| Any DMARDS ever, | 20 (33) | 14 (67) | 57 (95) | 0.008 | <0.0001 |
| csDMARDS ever, | 15 (25) | 7 (33) | 41 (68) | 0.46 | <0.0001 |
| MTX ever, | 9 (15) | 11 (52) | 48 (80) | 0.001 | <0.0001 |
| bDMARDS ever, | 4 (7) | 3 (14) | 25 (42) | 0.257 | <0.0001 |
| tsDMARDS ever, | 1 (2) | 0 (0) | 0 (0) | 0.741 | 0.5 |
t-test.
χ 2 test, or Fisher’s exact test with Bonferroni correction.
Mann–Whitney U test.
IQR: interquartile range; csDMARD: conventional synthetic DMARD; bDMARD: biological DMARD; tsDMARD: targeted synthetic DMARD. P-values were calculated for the difference between PMR-definite vs PMR-mimic or RA.
Fig. 1Prevalence of positive US scores at each joint site in PMR-definite, PMR-mimic and RA patients
Shown are the frequencies of positive GS scores (A) and power Doppler scores (B) at each joint site in patients in the PMR-definite, PMR-mimic and RA groups. GS score: greyscale score; PD score: power Doppler score; NA: not applicable; LHBT: long head of biceps tendon; SASDB: subacromial/subdeltoid bursa; GHJ: glenohumeral joint; SScT: subscapularis tendon; SSpT: supraspinatus tendon; SPB: suprapatellar bursa; MKJ: medial aspect of knee joint; LKJ: lateral aspect of knee joint; MCL: medial collateral ligament; LCL: lateral collateral ligament; PopT: popliteus tendon.
Prevalence of baseline abnormal US findings for tenosynovitis, tendinitis and ligament inflammation in PMR-definite, PMR-mimic and RA groups
| Present either unilaterally or bilaterally | Present bilaterally | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PMR-definite | PMR-mimic | RA |
| PMR-definite | PMR-mimic | RA |
| |||
|
|
|
|
| |||||||
| Shoulder component, | ||||||||||
| LHBT | 53 (88) | 3 (14) | 22 (37) | <0.001 | <0.001 | 42 (70) | 1 (5) | 10 (17) | <0.001 | <0.001 |
| SScT | 39 (65) | 0 (0) | 7 (12) | <0.001 | <0.001 | 18 (30) | 0 (0) | 1 (2) | 0.002 | <0.001 |
| SSpT | 39 (65) | 2 (10) | 6 (10) | <0.001 | <0.001 | 20 (33) | 0 (0) | 3 (5) | 0.002 | <0.001 |
| Shoulder combination, | ||||||||||
| Tendinitis (SScT and/or SSpT) | 50 (83) | 2 (10) | 12 (20) | <0.001 | <0.001 | 28 (47) | 0 (0) | 4 (7) | <0.001 | <0.001 |
| Any (LHBT, SScT and/or SSpT) | 58 (97) | 5 (24) | 27 (45) | <0.001 | <0.001 | 50 (83) | 1 (5) | 11 (18) | <0.001 | <0.001 |
| Knee component, | ||||||||||
| MCL | 29 (48) | 0 (0) | 5 (8) | <0.001 | <0.001 | 18 (30) | 0 (0) | 1 (2) | 0.002 | <0.001 |
| LCL | 35 (58) | 0 (0) | 11 (18) | <0.001 | <0.001 | 19 (32) | 0 (0) | 6 (10) | 0.001 | 0.003 |
| PopT | 53 (88) | 1 (5) | 19 (32) | <0.001 | <0.001 | 40 (67) | 0 (0) | 10 (17) | <0.001 | <0.001 |
| Knee combination, | ||||||||||
| Ligament (MCL and/or LCL) | 42 (70) | 0 (0) | 13 (22) | <0.001 | <0.001 | 28 (47) | 0 (0) | 6 (10) | <0.001 | <0.001 |
| Any (MCL, LCL and/or PopT) | 54 (90) | 1 (5) | 23 (38) | <0.001 | <0.001 | 47 (78) | 0 (0) | 11 (18) | <0.001 | <0.001 |
| All combinations, | ||||||||||
| Any shoulder (LHBT, SScT, SSpT) or any knee (MCL, LCL, PopT) | 58 (97) | 6 (29) | 36 (60) | <0.001 | <0.001 | 57 (95) | 1 (5) | 18 (30) | <0.001 | <0.001 |
| Any shoulder (LHBT, SScT, SSpT) and any knee (MCL, LCL, PopT) | 54 (90) | 0 | 14 (23) | <0.001 | <0.001 | 40 (67) | 0 (0) | 4 (7) | <0.001 | <0.001 |
P-values were calculated by χ2 test or Fisher’s exact test for the difference between PMR-definite vs PMR-mimic or RA with Bonferroni correction. LHBT: long head of biceps tendon; SScT: subscapularis tendon; SSpT: supraspinatus tendon; MCL: medial collateral ligament; LCL: lateral collateral ligament; PopT: popliteus tendon.
Modified classification criteria for PMR incorporating US findings in shoulder and knee
| Criteria | 2012 ACR/EULAR clinical classification criteria without US | 2012 ACR/EULAR classification criteria including shoulder and knee US |
|---|---|---|
| Morning stiffness duration >45 min | 2 | 2 |
| Hip pain or limited range of motion | 1 | 1 |
| Absence of RF or ACPA | 2 | 2 |
| Absence of other joint involvement | 1 | 1 |
| Bilateral shoulder involvement (biceps tenosynovitis | 1 | |
| Bilateral knee involvement (popliteus tenosynovitis | 1 |
The optimal cut point is 4. A patient with a score of ≥4 is categorized as having PMR.
The optimal cut point is 5. A patient with a score of ≥5 is categorized as having PMR.
Moderate or severe greyscale tenosynovitis and/or any tenosynovial Doppler signals.
Any Doppler signals in the tendon or ligament.
Fig. 2Receiver operator characteristic curves for the 2012 EULAR/ACR criteria without and with shoulder-knee US to classify patients in PMR-definite group
Accuracy of classification criteria for diagnosis of PMR with shoulder and knee US
| 2012 ACR/EULAR clinical classification criteria without US | 2012 ACR/EULAR classification criteria with shoulder and knee US | |
|---|---|---|
| Area under the ROC curve (95% CI) | 0.876 (0.820, 0.933) | 0.942 (0.905, 0.979) |
| Sensitivity, % (95% CI) | 87 (79, 96) | 90 (82, 98) |
| Specificity, % (95% CI) | 68 (58, 78) | 83 (75, 91) |
| Positive predictive value, % (95% CI) | 67 (57, 77) | 79 (74, 84) |
| Negative predictive value, % (95% CI) | 87 (79, 95) | 92 (86, 98) |
ROC: receiver operating characteristic.